Edit |   |
---|---|
Antigenic Specificity | CALCA/CALCB (Eptinezumab biosimilar) |
Clone | monoclonal |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | IgG1 kappa |
Format | Protein A/G purified |
Size | 100 µg, 1 mg, |
Concentration | typically between 0.5-2.0 mg/ml. |
Applications | ELISA, WB |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Eptinezumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CALCA/CALCB, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Eptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (Pichia pastoris) and developed by Lundbeck Seattle Biopharmaceuticals. 7 Eptinezumab has been specifically designed to bind to both alpha and beta forms of the human calcitonin gene-related peptide (CGRP). 8, 1, 2, 3 It was approved by the FDA in February 2020 for the preventive treatment of migraine headaches in adults. |
Immunogen | n/a |
Other Names | Eptinezumab, CALCA/CALCB, 1644539-04-7 |
Gene, Accession # | CAS: 1644539-04-7 |
Catalog # | abx831395 |
Price | please inquire |
Order / More Info | CALCA/CALCB (Eptinezumab biosimilar) Antibody from ABBEXA LTD |
Product Specific References | n/a |
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950